NIAID Continues Recruitment for Phase 1 Trial of Benlysta in Idiopathic CD4 Lymphocytopenia
Clinical Status and Patient Population
The NIAID-led Phoebe study, NCT04097561, is an open-label, single-arm Phase 1 trial enrolling 20 adults with idiopathic CD4 lymphocytopenia (ICL) who have detectable autoantibodies. Initiated in January 2020, recruitment is ongoing with a renewal deadline in April 2026, and the primary completion and study end dates are set for March 25, 2027. ICL is a rare condition characterized by CD4 T-cell counts below 300 cells/μL or less than 20% of total lymphocytes, with exclusion of HIV infection and other causes of immunodeficiency. It poses clinical burdens through opportunistic infections, autoimmune diseases, and cancer risks.
Benlysta's Mechanism and Trial Design
Benlysta (belimumab) is a fully human monoclonal antibody that selectively inhibits B-cell activating factor (BAFF/BLyS). Participants receive 10 mg/kg intravenously at weeks 0, 2, and 4, followed by a total of 8 doses at 4-week intervals. Safety and immunological changes are evaluated over 52 weeks, including up to 1 year after the last dose. The primary endpoint is the incidence of drug-related adverse events between weeks 2 and 48, while exploratory endpoints include CD4, CD8, NK, and B-cell counts, serum BAFF levels, and changes in autoantibodies and autoimmune conditions.
Scientific Hypothesis and Competitive Landscape
This trial tests the hypothesis that suppressing autoreactive B-cell pathways in a subset of ICL patients with confirmed anti-lymphocyte autoantibodies can reduce immune cell depletion. There is no established standard of care, and current clinical management primarily focuses on opportunistic infection treatment and antimicrobial prophylaxis. A prior recombinant human IL-7 (CYT107) Phase 1/2a trial evaluated CD4 T-cell expansion. The current competitive program is NIAID and NeoImmuneTech’s long-acting IL-7 efineptakin alfa (NT-I7) in Phase 1/2, NCT05600920, which aims to enroll 60 participants and complete in November 2026.
Regulatory and Commercial Implications
GSK plc’s Benlysta was first approved by the FDA for adult systemic lupus erythematosus (SLE) on March 9, 2011, with a 13-2 advisory committee vote in favor. The FDA expanded its indication to pediatric SLE in April 2019 and to adult lupus nephritis in December 2020, but its use in ICL remains in Phase 1. ICL itself is an ultra-rare disease, so commercial success hinges more on biomarker-driven label expansion than large-scale sales. The comparable SLE market was valued at USD 2.7 billion in 2024, with Benlysta sales at USD 1.9 billion.
The single-arm Phase 1 trial with 20 participants is primarily focused on establishing safety and biological rationale for future trials, particularly in terms of autoantibody and immune cell changes. Benlysta, a marketed asset with USD 1.9 billion in 2024 sales, already has well-established development, manufacturing, and regulatory infrastructure. However, the rarity of ICL and the selectivity of autoantibody-positive patients limit its commercial scale. The competitive landscape includes current infection-prevention-focused management and the NIAID·NeoImmuneTech efineptakin alfa Phase 1/2 trial. Belimumab targets B-cell autoimmunity, while NT-I7 focuses on T-cell proliferation, offering differentiated strategies. Positive 2027 safety results could provide GSK with a foundation for biomarker-based expansion into rare immune diseases and offer researchers validation of the BAFF/BLyS pathway in ICL pathophysiology.
Source: ClinicalTrials.gov (api_ct)